← Back to Clinical Trials
Recruiting NCT06989320

NCT06989320 Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06989320
Status Recruiting
Phase
Sponsor University of Alabama at Birmingham
Condition Kidney Stones
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2025-05-27
Primary Completion 2030-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Low-oxalate diet and glycolate dosingOral glycolate dosingOral 13C- ascorbic acid dosing

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2025-05-27 with a primary completion date of 2030-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial study is to test if patients with idiopathic calcium oxalate kidney stones have an increased production of oxalate by the body, which would lead to increased urinary excretion of oxalate. The study will recruit adult patients with a history of calcium oxalate kidney stones and healthy volunteers without kidney stones. Participants will ingest fixed diets containing low amounts of oxalate for 5 days ingest a soluble form of glycolate and vitamin C collect urine, blood, stool during the dietary and oral dosing portions of the study and also collect breath sample during the oral glycolate test

Eligibility Criteria

Inclusion Criteria: * age 18-80 yrs * Body Mass Index \> 18.5 kg/m2 * Normal fasting serum electrolytes on comprehensive metabolic profile * Willing to ingest fixed diets * Willing to stop supplements (vitamins including vitamin C, calcium (citrate or carbonate) and other minerals, herbal supplements, nutritional aids, probiotics) for 2 weeks before start and during study. * For stone formers: first time or recurrent Calcium Oxalate stone former. Composition of most recent stone ≥ 50% calcium oxalate if available, uric acid component \<20% Exclusion Criteria: * Chronic Kidney Disease stage 4-5 * Primary hyperoxaluria, Enteric (secondary) hyperoxaluria * Liver, bowel, endocrine or renal diseases (other than idiopathic Calcium Oxalate kidney stones) or any other condition that may influence the absorption, transport or urinary excretion of ions, which will compromise the interpretation of results, including: Cystic fibrosis, Celiac disease, Cystinuria, Uric acid stone former, Nephrotic syndrome, Sarcoidosis, Renal tubular acidosis, Primary hyperparathyroidism, Neurogenic bladder, Urinary diversion, Chronic diarrhea, Bariatric surgery, Inflammatory bowel disease * Pregnancy or breast-feeding * Incompatible dietary requirements with the study, food allergies or intolerance to any of the foods in study menus * Active malignancy or treatment for malignancy within 12 months prior to screening * Utilization of immunosuppressive medication * Uncontrolled hypertension or diabetes * Diabetes type 1

Contact & Investigator

Central Contact

Sonia Fargue, PhD

✉ sfargue@uabmc.edu

📞 205-975-6932

Principal Investigator

Sonia Fargue, PhD

PRINCIPAL INVESTIGATOR

University of Alabama at Birmingham

Frequently Asked Questions

Who can join the NCT06989320 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Kidney Stones. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06989320 currently recruiting?

Yes, NCT06989320 is actively recruiting participants. Contact the research team at sfargue@uabmc.edu for enrollment information.

Where is the NCT06989320 trial being conducted?

This trial is being conducted at Birmingham, United States, Dallas, United States.

Who is sponsoring the NCT06989320 clinical trial?

NCT06989320 is sponsored by University of Alabama at Birmingham. The principal investigator is Sonia Fargue, PhD at University of Alabama at Birmingham. The trial plans to enroll 80 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology